Press news

MABA Founder Yaniv Sneor on TEN Capital Network – The Relationship between Funding and Exit Paths

Early-stage life sciences companies are increasingly in the spotlight these days, with an uptick in investor interest and M&A activity in the space.

In “The Relationship between Funding and Exit Paths”, MABA founder Yaniv Sneor shares some background about our group and discusses potential exit strategies a young life science company may consider and how an exit strategy will, in most cases, determine the funding

2024-02-04T18:54:14+00:00February 4th, 2024|

MABA Portfolio Company FEMSelect Unveils Positive Study Results for Its EnPlace Pelvic Organ Prolapse Repair System

In a recently published article in the International Journal of Gynecology & Obstetrics (IJGO), FEMSelect announced positive results for their EnPlace system. The research was presented during the 2023 International Urogynecology Association 48th Annual Meeting in The Hague, Netherlands. FEMSelect’s EnPlace system offers a new, minimally invasive technique for addressing pelvic organ prolapse without the need for extensive surgery or mesh.

The study titled The EnPlace® sacrospinous ligament fixation—A novel minimally invasive transvaginal procedure for apical pelvic organ prolapse repair: Safety and short-term outcome results, focused on the safety and efficacy of the EnPlace system, a device cleared by the FDA [ Read more… ]

2023-08-29T19:30:18+00:00August 29th, 2023|

MABA Portfolio Company Astrocyte Pharmaceuticals Raises $6M Pre-Series B Financing Round

Alzheimer’s Drug Discovery Foundation Joins Astrocyte Pharmaceuticals’ $6M Pre-Series B Financing Round to Expand Development of Cerebroprotectant AST-004

August 18, 2023 12:39 PM Eastern Daylight Time

GROTON, Conn.–(BUSINESS WIRE)–Astrocyte Pharmaceuticals Inc., a clinical-stage drug discovery and development company advancing novel cerebroprotective therapeutics for patients with brain injuries, announced an oversubscribed pre-Series B Bridge financing round of over $6M that was led by Dreavent Capital, and joined by the Alzheimer’s Drug Discovery Foundation, and other investors. The funding will accelerate the clinical development of AST-004, a highly promising therapeutic candidate aimed at treating a broad array of acute brain injuries including stroke and [ Read more… ]

2023-08-29T19:27:52+00:00August 26th, 2023|

MABA’s 2023 ACA Innovation Nominee TSSC Honored with Prestigious Luis Villalobos Award

NEW YORK CITY, NEW YORK, UNITED STATES OF AMERICA, May 31, 2023/EINPresswire.com/ — Mid Atlantic Bio Angels (MABA), a NY-based life angel investor group, is pleased to announce that its nominee The Shape Sensing Company (TSCC) has received the prestigious 2023 Luis Villalobos Award in recognition of industry innovation by disruptive companies operating at the forefront of their respective fields, who have been recently financed by members of the Angel Capital Association (ACA).

The award is in honor of Luis Villalobos, founder of [ Read more… ]

2023-06-01T17:25:30+00:00May 31st, 2023|

MedCity INVEST Ask the Investor Spotlight: Yaniv Sneor of Mid Atlantic Bio Angels

Yaniv Sneor, the co-founder of Mid Atlantic Bio Angels and part of the Ask the Investor sessions at MedCity INVEST this week, explained what his firm looks for in life science startups.

Healthcare and life science startups have the opportunity to network and engage in salon-style discussions with investors as part of the Ask the Investor sessions. They will be held during the breakfast segments of INVEST on [ Read more… ]

2023-06-01T11:57:19+00:00May 23rd, 2023|

MABA Portfolio Company Cerus Endovascular Acquired by Stryker

NEW YORK CITY, NY, USA, May 9, 2023/EINPresswire.com/ — Mid Atlantic Bio Angels (MABA), a NY-based life science angel investor group, announced today that one of its portfolio companies, Cerus Endovascular Ltd, was acquired in a large transaction by Stryker. Cerus Endovascular Ltd, a UK-based, privately held, commercial stage medical device company focused on the design and development of neurointerventional devices for the treatment of intracranial aneurysms, will join the portfolio of Stryker, one of the world’s leading medical technology companies.

MABA’s investment in Cerus Endovascular (Cerus) underscores its commitment to supporting companies that it believes will greatly elevate the standard [ Read more… ]

2023-05-25T09:12:36+00:00May 9th, 2023|

Mid Atlantic Bio Angels Invests in Veterinary Biotech Company Hilltop Bio

Mid Atlantic Bio Angels, a NY-based angel investor group, is investing in Hilltop Bio, a veterinary biotech company. The MABA investment includes individual investors; MABA’s internal investment Pool III; and the MABA Sidecar Fund II, a co-investment fund for non-MABA members

Hilltop Bio’s products, in development and commercialized, are regenerative therapies that help reduce pain, inflammation, healing time, scar tissue, and reinjury rates. Equine and small animal veterinarians benefit due to the ease of everyday use, storage, and consistent product profile. Veterinarians can also reduce the number of visits a client makes [ Read more… ]

2023-04-08T20:05:54+00:00March 31st, 2023|

MABA Invests in 3D Shape Sensing Technology

NEW YORK CITY, NEW YORK, UNITED STATES, November 10, 2022 /EINPresswire.com/ — Mid Atlantic Bio Angels Group (MABA) is pleased to announce that it has made an investment in The Shape Sensing Company (TSSC).

TSSC joins a prestigious, carefully selected, group of companies and organizations that reflects MABA’s core mission of supporting early-stage health care entrepreneurs and generating favorable financial returns for its members and investors. The MABA investment included individual investors, MABA’s internal investment Pool III, and the MABA Sidecar Fund II, a co-investment fund for non-MABA members.

“Throughout our due diligence process, TSSC’s strong management and transformative technology received notable [ Read more… ]

2023-04-08T20:09:41+00:00November 11th, 2022|
Go to Top